In Vitro and In Vivo Activity of Ribavirin against Andes Virus Infection
Open Access
- 10 August 2011
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 6 (8), e23560
- https://doi.org/10.1371/journal.pone.0023560
Abstract
Pathogenic hantaviruses are a closely related group of rodent-borne viruses which are responsible for two distinct diseases in humans, hemorrhagic fever with renal syndrome and hantavirus pulmonary syndrome (HPS, otherwise known as hantavirus cardiopulmonary syndrome, HCPS). The antiviral effect of ribavirin against Old World hantaviruses, most notably Hantaan virus, is well documented; however, only a few studies have addressed its inhibitory effect on New World hantaviruses. In the present study, we demonstrate that ribavirin is highly active against Andes virus (ANDV), an important etiological agent of HPS, both in vitro and in vivo using a lethal hamster model of HPS. Treatment of ANDV infected Vero E6 cells with ribavirin resulted in dose-dependent reductions in viral RNA and protein as well as virus yields with a half maximal inhibitory concentration between 5 and 12.5 µg ml−1. In hamsters, treatment with as little as 5 mg kg−1 day−1 was 100% effective at preventing lethal HPS disease when therapy was administered by intraperitoneal injection from day 1 through day 10 post-infection. Significant reductions were observed in ANDV RNA and antigen positive cells in lung and liver tissues. Ribavirin remained completely protective when administered by intraperitoneal injections up to three days post-infection. In addition, we show that daily oral ribavirin therapy initiated 1 day post-infection and continuing for ten days is also protective against lethal ANDV disease, even at doses of 5 mg kg−1 day−1. Our results suggest ribavirin treatment is beneficial for postexposure prophylaxis against HPS-causing hantaviruses and should be considered in scenarios where exposure to the virus is probable. The similarities between the results obtained in this study and those from previous clinical evaluations of ribavirin against HPS, further validate the hamster model of lethal HPS and demonstrate its usefulness in screening antiviral agents against this disease.Keywords
This publication has 30 references indexed in Scilit:
- Validation of assays to monitor immune responses in the Syrian golden hamster (Mesocricetus auratus)Journal of Immunological Methods, 2011
- A Global Perspective on Hantavirus Ecology, Epidemiology, and DiseaseClinical Microbiology Reviews, 2010
- Adenovirus Vectors Expressing Hantavirus Proteins Protect Hamsters against Lethal Challenge with Andes VirusJournal of Virology, 2009
- Role of mixed Th1 and Th2 serum cytokines on pathogenesis and prognosis of hantavirus pulmonary syndromeMicrobes and Infection, 2008
- Treatment of hantavirus pulmonary syndromeAntiviral Research, 2007
- Ribavirin Reveals a Lethal Threshold of Allowable Mutation Frequency for Hantaan VirusJournal of Virology, 2007
- In Vitro and In Vivo Activities of T-705 against Arenavirus and Bunyavirus InfectionsAntimicrobial Agents and Chemotherapy, 2007
- Temporal Analysis of Andes Virus and Sin Nombre Virus Infections of Syrian HamstersJournal of Virology, 2007
- Activity of Ribavirin against Hantaan Virus Correlates with Production of Ribavirin-5′-Triphosphate, Not with Inhibition of IMP DehydrogenaseAntimicrobial Agents and Chemotherapy, 2007
- Ribavirin Causes Error Catastrophe during Hantaan Virus ReplicationJournal of Virology, 2003